Six numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
the abstract, start to end
… HbA1c (weighted mean difference WMD -0.69 %; 95 % CI -0.83 to -0.56 %; I (2) = 82 %), and it was as effective as other antidiabetic agents (WMD -0.01 %; 95 % CI -0.16 to 0.14 %; I (2) = 93 %), without increasing the risk for hypoglycemia (OR 0.83; 95 % CI 0.59 to 1.16; I (2) = 0 % vs. placebo, and OR 0.19; 95 % CI 0.15 to 0.24; I (2) = …
… the incidence of pancreatitis (OR 0.97; 95 % CI 0.37 to 2.53; I (2) = 0 %), serious adverse events (OR 0.98; 95 % CI 0.88 to 1.09; I (2) = 0 %) or death (OR 1.10, 95 % CI 0.75 to 1.61; I (2) = …
← favours treatmentfavours comparator →
could be chanceHypoglycaemia
−0.69−0.83 to −0.56
Adverse events & safety
OR 0.970.37–2.53
Hypoglycaemia
OR 0.830.59–1.16
Adverse events & safety
OR 0.980.88–1.09
Adverse events & safety
OR 1.100.75–1.61
Hypoglycaemia
OR 0.190.15–0.24
DPP-4 inhibitorsOther glucose-loweringAdverse events & safetyHypoglycaemia
DPP-4 inhibitors × adverse events & safetyharms?mixed
unlikelylikely
0.00not counted
← favours comparatorfavours treatment →
1 / 5